Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
153.45
+3.14 (+2.09%)
Streaming Delayed Price
Updated: 11:29 AM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
May 04, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
April 28, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
April 14, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
April 05, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
April 04, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
March 22, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
March 17, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Issues 2021 Corporate Responsibility Report
March 16, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
February 28, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
February 10, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
January 24, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
January 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
January 14, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
January 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
January 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
January 04, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
December 22, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
December 22, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
December 21, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
December 20, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
December 20, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
December 14, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
December 02, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming Investor Conferences
November 23, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
November 19, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
November 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
November 12, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
November 08, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.